Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-12-06
2000-02-29
McKane, Joseph K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514378, 514379, 514247, 514252, 514365, 514369, 514370, 514372, 514374, 514375, 514376, 514377, 514602, 514604, 544224, 544238, 548146, 548182, 548190, 548202, 548203, 548205, 548206, 548213, A61K 3142, C07D26110
Patent
active
060309911
ABSTRACT:
N-(5-isoxazolyl)benzenesulfonamides and N-(3-isoxazolyl) benzene-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(5-isoxazolyl)-biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. N-isoxzolyl-4-biphenylsulfonamides are particularly preferred. These compounds exhibit activity as endothelin receptor B antagonists. Methods for treating endothelin-mediated disorders, particularly inflammatory diseases, such as asthma, by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
REFERENCES:
patent: 2888455 (1959-05-01), Kano et al.
patent: 3300488 (1967-01-01), Onoue et al.
patent: 3660383 (1972-05-01), Sumimoto et al.
patent: 4044126 (1977-08-01), Cook et al.
patent: 4364923 (1982-12-01), Cook et al.
patent: 4414209 (1983-11-01), Cook et al.
patent: 4485108 (1984-11-01), Jozic
patent: 4752613 (1988-06-01), Floyd et al.
patent: 4997836 (1991-03-01), Sugihara et al.
patent: 5082838 (1992-01-01), Naka et al.
patent: 5114918 (1992-05-01), Ishikawa et al.
patent: 5187195 (1993-02-01), Oohata
patent: 5198548 (1993-03-01), Beylin et al.
patent: 5208243 (1993-05-01), Peglion et al.
patent: 5230999 (1993-07-01), Suzuki et al.
patent: 5240910 (1993-08-01), Lam et al.
patent: 5248807 (1993-09-01), Fujimoto et al.
patent: 5270313 (1993-12-01), Burri et al.
patent: 5292740 (1994-03-01), Burri et al.
patent: 5334598 (1994-08-01), Bagley et al.
patent: 5352659 (1994-10-01), Wakimasu et al.
patent: 5352800 (1994-10-01), Bills et al.
patent: 5378715 (1995-01-01), Stein et al.
patent: 5382569 (1995-01-01), Cody et al.
patent: 5389620 (1995-02-01), Ishikawa et al.
patent: 5389633 (1995-02-01), Miyake et al.
patent: 5407941 (1995-04-01), Carceller et al.
patent: 5420123 (1995-05-01), Murugesan
patent: 5420129 (1995-05-01), Breu et al.
patent: 5420131 (1995-05-01), Carceller et al.
patent: 5420133 (1995-05-01), Dhanoa et al.
patent: 5420138 (1995-05-01), Corbier et al.
patent: 5420275 (1995-05-01), Masuya et al.
patent: 5464853 (1995-11-01), Chan et al.
patent: 5514691 (1996-05-01), Chan et al.
patent: 5514696 (1996-05-01), Murugesan et al.
patent: 5565485 (1996-10-01), Bagley et al.
patent: 5585397 (1996-12-01), Tung et al.
patent: 5589478 (1996-12-01), Yamada et al.
patent: 5591728 (1997-01-01), de Nanteuil et al.
patent: 5599811 (1997-02-01), Berryman et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5641793 (1997-06-01), Bradbury
patent: 5668137 (1997-09-01), Phillips et al.
patent: 5668176 (1997-09-01), Bagley et al.
patent: 5726194 (1998-03-01), Osswald et al.
patent: 5783105 (1998-07-01), Blok et al.
patent: 5827869 (1998-10-01), Murugesan
Official Gazette Notice, Jul. 7, 1998, "Adverse Decisions in Interference", Interference No. 103,876.
Allen, et al., "The Cambridge crystallographic data centre: Computer-based search, retrieval, analysis and display of Information," Acta Crystallogr., B35:2331-2339 (1979).
Anagnostou, et al., "Erythropoietin has mitogenic and positive chemotactic effects on endothelial cells," P.N.A.S., 87:5978-5982 (1990).
Arai, et al., "Cloning and expression of a cDNA encoding an endothelin receptor," Nature, 348:730-732 (1990).
Aumelas, et al., "Determination of the structure of [Nle.sup.7 ]-endothelin by .sup.1 H NMR," Int. J. Peptide Protein Res., 37:315-324 (1991).
Balasubramanian, R., "New type of representation for mapping chain folding in protein molecules," Nature, 266:856-857 (1977).
Benigni, et al., "A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression," Kidney International, 44:440-444 (1993).
Bolger, et al., "Characterization of binding of the Ca.sup.++ channel antagonist [.sup.3 H] nitrendipine, to guinea-pig ileal smooth muscle," J. of Pharmacology and Experimental Therapeutics, 225:291-309 (1983).
Borges, et al., "Tissue selectivity of endothelin," Eur. J. of Pharmacology, 165:223-230 (1989).
Brint, et al., "Upperbound procedures for the identification of similar three-dimensional chemical structures," J. Comput.-Aided Mol. Design, 2:311-310 (1988).
Brooks, et al., "Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number," Eur. J. of Pharmacology, 194:115-117 (1991).
Buemi, et al., "Influence of recombinant erythropoietin on the production of endothelin-1 from human umbilical artery," Nephron, 64(1):165-166 (1993).
Cardell, et al., "Two functional endothelin receptors in guinea-pig pulmonary arteries," Neurochem. Int., 18(4):571-574 (1991).
Carlini, et al., "Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients," Am. J. Hyper., 6:103-107 (1993).
Clarke, et al., "Endothelin is a potent long-lasting vasoconstrictor in men," Am. J. Physiol., 257(6 pt 2):H2033-H2035 (1989).
Cody, et al., "The rational design of a highly potent combined ET.sub.A and ET.sub.B receptor antagonist (PD145065) and related analogues," Med. Chem. Res., 3:154-162 (1993).
Cooper, et al., "A novel approach to molecular similarity," J. Comput.-Aided Mol. Design, 3:253-259 (1989).
De Nucci, et al., "Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor," Proc. Natl. Acad. Sci., 85:9797 (1988).
Doherty, "Endothelin: A new challenge," J. Medicinal Chem., 35(9):1493-1508 (1992).
Eschbach, et al., "Recombinant human erythropoietin in anemic patients with end stage renal disease; results of a phase III multicenter clinical trial," Ann. Intern. Med., 111:992-1000 (1989).
Filep, et al., "Endothelin-1 induces prostacyclin release from bovine aortic endothelial cells," Biochem. and Biophys. Research Comm., 177(1):171-176 (1991).
Fujimoto, et al., "A novel non-peptide endothelin antagonist isolated from bayberry," FEBS, 305(1):41-44 (1992).
Fujimoto, et al., "Isoxazole derivatives. II. Synthesis and structure of N-acylsufodiazoles and their homologs," Chemical Abstracts, vol. 65, No. 2, Jul. 18, 1966, Abstract No. 2241eq.
Galantino, et al., "D-Amino acid scan of endothelin," Peptides: Chemistry & Biology, Proc. Amer. Report. Symp. (Twelfth), J.A. Smith and J.E. Rivier, Eds., ESCOM, Leiden, 1992, pp. 404-405.
Gu, et al., "The inhibitory effect of [D-Arg.sup.1, D-Phe, D-Try.sup.7,9, Leu.sup.11 ] substance P on endothelin-1 binding sites in rat cardiac membranes," Biochem. and Biophys. Research Commun., 179(1):130-133 (1991).
Heidenreich, et al., "Erythropoietin induces contraction of isolated renal small resistance vessels," Nephrol. Dial. Transplant, 5:739-740 (1990).
Hiley, et al., "Functional studies on endothelin catch up with molecular biology," Trends Pharmacol. Sci., 10:47-49 (1989).
Hirata, et al., "Receptor binding activity and cytosolic free calcium response by synthetic endothelin analogs in culture rat vascular smooth muscle cells," Biochem. and Biophys. Research Commun., 160:228-234 (1989).
Hori, et al., "Hemodynamics and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients," Clin. Nephrol., 33:293-298 (1990).
Ihara, et al., "An endothelin receptor (ET.sub.A) antagonist isolated from Streptomyces Misakiensis," Biochem. and Biophys. Research Commun., 178(1):132-137 (1991).
Ihara, et al., "Biological profiles of highly potent novel endothelin antagonists selective for the ET.sub.A receptor," Life Sciences, 50:247-255 (1991).
Inoue, et al., "The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes," Proc. Natl. Acad. Sci. USA, 86:2863-2867 (1989).
Ishikawa, et al., "Cyclic pentapeptide endothelin antagonists with high ET.sub.A selectivity. Potency- and solubility-enhan
Balaji Vitukudi Narayanaiyengar
Castillo Rosario Silvestre
Chan Ming Fai
Kois Adam
Raju Bore Gowda
McKane Joseph K.
Seidman Stephanie L.
Texas Biotechnology Corp.
LandOfFree
Benzenesulfonamides and the use thereof to modulate the activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzenesulfonamides and the use thereof to modulate the activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzenesulfonamides and the use thereof to modulate the activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-683402